Last Updated: August 8, 2026

Claims for Patent: 11,602,512

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,602,512

Title:	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Abstract:	Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
Inventor(s):	Jordan Dubow, Hervé Guillard, Claire Mégret, Jean-François DUBUISSON
Assignee:	Flamel Ireland Ltd
Application Number:	US17/497,381
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,602,512
Patent Claims:	1. A method of treating cataplexy or excessive daytime sleepiness in a human subject with narcolepsy, the method comprising: administering to the subject a single daily dose of a gamma-hydroxybutyrate formulation comprising an immediate-release portion and a modified-release portion, wherein the single daily dose comprises an amount of gamma-hydroxybutyrate equivalent to 3.0 g, 4.5 g, 6 g, 7.5 g, or 9 g of sodium oxybate, wherein the administering occurs at bedtime, and wherein 2% or fewer subjects administered the formulation experience a confusional state. 2. The method of claim 1, wherein the subject has a decreased risk of falls or headaches. 3. The method of claim 1, wherein the subject has a decreased risk of car and work accidents. 4. The method of claim 1, wherein the subject has a decreased risk of work-related errors or lack of energy. 5. The method of claim 1, wherein the subject has a decreased risk of irritability or mood problems. 6. The method of claim 1, wherein the subject has a decreased risk of gastrointestinal, cardiovascular, or metabolic disorders. 7. The method of claim 1, wherein the subject has a decreased risk of drug or alcohol abuse. 8. The method of claim 1, wherein the subject has a decreased risk of one or more of the sleep deprivation side effects selected from the group consisting of lack of alertness, irritation, memory lapses, lack of focus, difficulty retaining new concepts, difficulty making decisions, slower reaction times, and combinations thereof. 9. The method of claim 1, where the subject has a decreased risk of developing diabetes, obesity, and heart disease associated with long-term sleep deprivation. 10. A method of treating cataplexy or excessive daytime sleepiness in a human subject with narcolepsy, the method comprising: administering to the subject a single daily dose of a gamma-hydroxybutyrate formulation comprising an immediate-release portion and a modified-release portion, wherein the single daily dose comprises an amount of gamma-hydroxybutyrate equivalent to 3.7 g, 5.0 g, 6.2 g, or 7.4 g of oxybate, wherein the administering occurs at bedtime, and wherein 3% or fewer subjects administered the formulation experience sleepwalking. 11. The method of claim 10, wherein the sleepwalking is a parasomnia that occurs during non-REM sleep.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.